More than 300 comments have been posted in response to a Department of Commerce investigation into the importation of certain pharmaceuticals and pharma ingredients.
PhRMA warned that President Trump’s executive order on most favored nation would jeopardize hundreds of billions of dollars in planned U.S. investments by its members.
The three Big Pharma companies on their earnings calls this week tried to reassure investors that they have the global footprints to mitigate the effects of tariffs.
President Trump has threatened to impose tariffs on pharmaceuticals, as a Department of Commerce probe on drug imports gets underway. But analysts and stakeholders are skeptical...
Despite Trump pushing drugmakers to bring manufacturing back to the U.S., it remains unclear whether companies — other than Eli Lilly, J&J, and Novartis — will respond.
The industry got a reprieve as pharmaceuticals were exempted from President Trump’s reciprocal tariffs announced this week. However, analysts expect it to be short-lived.
This week, President Donald Trump doubled down on his threat to target the pharma industry with tariffs meant to bring drug manufacturing back to the United States.
Major players in the contract development and manufacturing organization industry gathered in New York City this week to provide updates on their infrastructure investments.
Eli Lilly, Merck, Pfizer, Purdue University, and The Noramco Group are among the stakeholders looking to help address shortages in the U.S. injectable supply chain.
It’s been a topsy-turvy week for President Trump’s tariff proclamations, which have created anxiety and confusion for businesses that rely on trade with Canada and Mexico.
The Indiana-headquartered pharma giant chose to make its investment announcement this week in Washington, D.C., with newly confirmed Commerce Secretary Howard Lutnick.
In 2025, Charles River’s contract development and manufacturing organization business is set to struggle, while Siegfried’s growth outlook is fueled by strong demand.
India’s Global Calcium and China’s Wuhu Nuowei Chemistry and Chengdu Innovation Pharmaceutical are the latest to be hit with warning letters from U.S. regulators.
President Trump has for now suspended a 25% levy on imports from Canada, but the looming tariff threat was a hot topic of discussion at a life sciences summit in Toronto.
